Back to top
more

Enzo Biochem (ENZ)

(Delayed Data from NYSE)

$1.16 USD

1.16
87,843

+0.05 (4.50%)

Updated Jul 12, 2024 04:00 PM ET

After-Market: $1.16 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Clovis Oncology (CLVS) in Focus: Stock Moves 5.6% Higher

by Zacks Equity Research

Clovis Oncology, Inc. (CLVS) saw its shares rise above 5% in the last trading session.

    Vertex Pharma's (VRTX) Q4 Earnings & Sales Beat; Stock Up

    by Zacks Equity Research

    Vertex Pharmaceuticals Inc. (VRTX) reported fourth-quarter 2016 earnings of 11 cents per share (including the impact of stock-based compensation expenses). The Zacks Consensus Estimate was of a loss of 1 cent per share.

      Roche (RHHBY) Arthritis Drug Actemra sBLA Accepted by FDA

      by Zacks Equity Research

      Roche's (RHHBY) supplemental Biologics License Application (sBLA) for arthritis drug, Actemra, accepted for review by the FDA for giant cell arteritis (GCA).

        AbbVie's HCV Regimen Okayed for Accelerated Assessment

        by Zacks Equity Research

        AbbVie Inc. (ABBV) recently announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application for its investigational, pan-genotypic regimen of glecaprevir (ABT-493)/pibrentasvir (ABT-530) (G/P).

          Perrigo's (PRGO) Generic Version of Topicort Okayed by FDA

          by Zacks Equity Research

          Perrigo Company plc (PRGO) recently announced that the FDA has approved its first-to-file AB rated generic version of Taro Pharmaceuticals's Topicort spray, 0.25% indicated for the treatment of plaque psoriasis in patients of 18 years or above.

            Endo (ENDP) Settles Disputes with Federal Trade Commission

            by Zacks Equity Research

            Endo International plc (ENDP) announced that it has resolved all disputes with the U.S. Federal Trade Commission (FTC).

              Marinus Releases Positive Preliminary Data from CDKL5 Study

              by Zacks Equity Research

              Marinus Pharmaceuticals, Inc. (MRNS), announced positive preliminary data from the initial CDKL5 pediatric patients enrolled in its ongoing phase II study assessing pipeline candidate, ganaxolone, for the treatment of orphan, genetic disorders.

                Concert's (CNCE) CTP-656 Gets Orphan Drug Status in U.S.

                by Zacks Equity Research

                Concert Pharmaceuticals, Inc. (CNCE) announced that the FDA has granted orphan drug designation to its candidate CTP-656 for the treatment of cystic fibrosis.

                  Minerva Presents Additional Data from Schizophrenia Drug

                  by Zacks Equity Research

                  Minerva Neurosciences, Inc. (NERV) announced the results of additional data analyses from phase IIb clinical trial of MIN-101, as monotherapy in patients with negative symptoms of schizophrenia.

                    J&J Arm Buys Megadyne, Boosts Electrosurgical Tools Portfolio

                    by Zacks Equity Research

                    Ethicon Endo-Surgery, Inc. a subsidiary of Johnson & Johnson (JNJ), announced the acquisition of Megadyne Medical Products, Inc., a privately held medical device company.

                      Immunomedics (IMMU) Worth a Look: Stock Climbs 7%

                      by Zacks Equity Research

                      Immunomedics, Inc. (IMMU) shares rose almost 7% in the last trading session.

                        Aduro (ADRO) Inks License Agreement with Stanford University

                        by Zacks Equity Research

                        Aduro Biotech, Inc. (ADRO) announced that it has inked an exclusive license agreement with Stanford University for state-of-the-art neo-antigen identification technology.

                          Synergy (SGYP) Trulance Wins FDA Approval for Constipation

                          by Zacks Equity Research

                          Synergy Pharmaceuticals Inc. (SGYP) announced that the FDA has approved one of its lead pipeline candidates, Trulance (plecanatide), for the treatment of adults suffering from chronic idiopathic constipation (CIC).

                            Allergan (AGN) Rhofade Cream for Rosacea Approved in U.S.

                            by Zacks Equity Research

                            Allergan plc (AGN) announced that the FDA has approved Rhofade (oxymetazoline hydrochloride) cream for topical treatment of persistent facial erythema (redness) associated with rosacea in adults.

                              Abbvie (ABBV) Imbruvica Approved in Lymphoma Indication

                              by Zacks Equity Research

                              AbbVie Inc. (ABBV) announced that the FDA has approved its blood cancer drug, Imbruvica, for the treatment of patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL).

                                Mallinckrodt to Pay $100M Fine to FTC for Questcor Matter

                                by Zacks Equity Research

                                Mallinckrodt plc (MNK), will have to pay a fine of $100 million to the U.S. Federal Trade Commission (FTC) to resolve the latter???s investigation into the acquisition of Synacthen Depot by its Questcor division.

                                  Teva's (TEVA) Pain Drug Vantrela ER Receives FDA Approval

                                  by Zacks Equity Research

                                  Teva Pharmaceutical Industries Ltd. (TEVA) announced that the FDA has approved Vantrela ER for the treatment of pain which is severe enough to require daily, around-the-clock, long-term opioid treatment.

                                    Allergan's Uterine Fibroids Candidate Positive in Phase III

                                    by Zacks Equity Research

                                    Allergan Plc (AGN) and European specialty pharma company Gedeon Richter reported encouraging results from a phase III study on their pipeline candidate, ulipristal acetate, in women with abnormal bleeding due to uterine fibroids.

                                      Concert Offers Update on Cystic Fibrosis Drug, Stock Down

                                      by Zacks Equity Research

                                      Concert Pharmaceuticals, Inc. (CNCE) provided update on the development plan of its next generation CFTR potentiator, CTP-656, for the treatment of cystic fibrosis in the U.S. and Europe.

                                        Sanofi Diabetes Drug Suliqua Wins EU Marketing Approval

                                        by Zacks Equity Research

                                        Sanofi (SNY) announced that the European Commission has granted marketing authorization to its once-daily injection, Suliqua a combination of diabetes drugs Lantus and lixisenatide for the treatment of diabetes.

                                          Jazz Begins Phase III Study for Label Expansion of Defitelio

                                          by Zacks Equity Research

                                          Jazz Pharmaceuticals Public Limited Company (JAZZ) announced the initiation of a phase III clinical study on its marketed drug, Defitelio (defibrotide), for the potential prevention of veno-occlusive disease.

                                            Biogen to Pay $1.25B to Forward Pharma in Tecfidera Lawsuit

                                            by Zacks Equity Research

                                            Biogen Inc. (BIIB) recently entered into a settlement and license agreement with Danish biotech, Forward Pharma A/S (FWP) with respect to an ongoing patent dispute for Tecfidera.

                                              Biogen (BIIB) Presents Positive Phase III Data on Spinraza

                                              by Zacks Equity Research

                                              Biogen Inc. (BIIB) presented positive data from the phase III ENDEAR study evaluating Spinraza (nusinersen) for the treatment of spinal muscular atrophy (SMA).

                                                Lilly, Merck Expand Tie-Up to Study Lartruvo-Keytruda Combo

                                                by Zacks Equity Research

                                                Eli Lilly and Company (LLY) and Merck & Co., Inc. (MRK) expanded their existing immuno-oncology partnership to include a new study that will evaluate Lilly???s Lartruvo in combination with Merck???s Keytruda in patients with STS.

                                                  Amgen: Phase III Data on Hyperparathyroidism Drug Published

                                                  by Zacks Equity Research

                                                  Amgen Inc. (AMGN) announced that data from three phase III studies on its pipeline candidate, Parsabiv (etelcalcetide), were published in the Journal of the American Medical Association (JAMA).